Fat-Soluble Vitamin Supplementation in Primary Sclerosing Cholangitis
Yes, patients with primary sclerosing cholangitis should receive comprehensive fat-soluble vitamin supplementation including vitamins A, D, E, and K, particularly when overt cholestasis or steatorrhea is present.
Recommended Supplementation Regimen
Based on the most recent and authoritative guidelines for cholestatic liver disease, the following approach should be implemented 1, 2:
Vitamin D and Calcium (All PSC Patients)
- Vitamin D: 400-800 IU daily (enteral)
- Calcium: 1000-1200 mg daily
- These should be given to all PSC patients as part of osteoporosis prevention, regardless of cholestasis severity 2
Additional Fat-Soluble Vitamins (Based on Disease Severity)
For patients with overt cholestasis or steatorrhea 2:
- Vitamin A: 10,000-50,000 units daily
- Vitamin E: 30 IU daily
- Vitamin K: 10 mg weekly (oral)
Parenteral vitamin K should be given prophylactically before any invasive procedures and in bleeding contexts 2
Clinical Context and Rationale
The 2019 BSG/UK-PSC guidelines specifically note that advanced cholestasis in PSC can result in malabsorption of fat-soluble vitamins 1. Research demonstrates that vitamin deficiencies are extremely common in PSC, with one study showing 40% had vitamin A deficiency, 14% had vitamin D deficiency, and 2% had vitamin E deficiency in early disease 3. In advanced PSC patients being evaluated for transplant, deficiencies were far more severe: 82% deficient in vitamin A, 57% in vitamin D, and 43% in vitamin E 3.
Recent data from 2025 confirms this remains a significant problem, with more than half of PSC patients reporting suboptimal intake of vitamins D and K, and over 30% having inadequate intake of vitamins A and E 4.
Important Caveats and Monitoring
When to Supplement More Aggressively
The EASL 2009 guidelines specify that vitamins A, E, and K supplementation is particularly indicated when 2:
- Clinical features of steatorrhea are present
- Overt cholestasis exists
- Fat-soluble vitamin levels are proven to be low
Toxicity Concerns
Exercise caution with vitamins A and D due to potential toxicity, especially in patients with cholestatic liver disease 5. The ESPEN micronutrient guidelines emphasize that fat-soluble vitamins (particularly A and D) have toxicity potential unlike water-soluble vitamins 5.
Copper and Manganese Reduction
In PSC patients with cholestasis, copper and manganese should be reduced if providing parenteral nutrition, as these accumulate in cholestatic conditions 5.
Routine Assessment
The 2019 BSG guidelines recommend risk assessment for osteoporosis in all PSC patients, with DEXA scanning for high-risk individuals 1. The EASL 2009 guidelines suggest DEXA at presentation with rescreening up to annually depending on cholestasis severity 2.
Emerging Evidence
A 2026 study found that vitamin D supplementation was associated with an 84-85% reduction in hepatobiliary malignancy risk in PSC patients (HR 0.15-0.16), with 5-year cumulative incidence of malignancy of only 1.1% in supplemented patients versus 11.5% without supplementation 6. This provides additional rationale for universal vitamin D supplementation in PSC beyond bone health considerations.
Practical Implementation
Rather than routinely checking vitamin levels (which is "not widely used and is not recommended" per EASL guidelines 2), the more practical approach is:
- Universal supplementation: Vitamin D 400-800 IU + Calcium 1000-1200 mg daily for all PSC patients
- Add comprehensive fat-soluble vitamins (A, E, K) when bilirubin is elevated, steatorrhea develops, or disease advances
- Parenteral vitamin K before procedures or with coagulopathy
- Monitor bone density rather than vitamin levels to guide therapy intensity